Theravance Biopharma (TBPH) Institutional Ownership

99.10% of Theravance Biopharma's stock is owned by institutional investors. Learn more on TBPH's institutional investor holdings.

Of the 136 institutional investors that purchased Theravance Biopharma's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Arrowstreet Capital Limited Partnership ($726.78K), Dimensional Fund Advisors LP ($448.53K), Assenagon Asset Management S.A. ($414.72K), JPMorgan Chase & Co. ($398.11K), Nuveen LLC ($374.95K), Pacer Advisors Inc. ($338.96K), and Hillsdale Investment Management Inc. ($310.70K).

Institutional investors have bought a total of 7,793,526 shares in the last 24 months. This purchase volume represents approximately $122.07M in transactions.

Of the 47 institutional investors that sold Theravance Biopharma's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Park West Asset Management LLC ($1.62M), Arrowstreet Capital Limited Partnership ($635.71K), Camber Capital Management LP ($550K), Citadel Advisors LLC ($434.46K), Oasis Management Co Ltd. ($391.77K), Tudor Investment Corp ET AL ($291.03K), and Jane Street Group LLC ($98.12K).

Institutional investors have sold a total of 4,591,845 shares in the last 24 months. This volume of shares sold represents approximately $72.93M in transactions.